ArticleBritish journal of cancer2026
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrediction of surgical and survival outcomes following neoadjuvant chemotherapy (NACT) in ovarian cancer remains challenging. This study evaluated whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) after NACT for predicting complete resection at interval debulking surgery (IDS), progression-free survival, and overall survival.
methodsIn this prospective, single-centre study, 105 patients with non-primary resectable ovarian cancer underwent WB-DWI/MRI following NACT. The performance of WB-DWI/MRI in predicting complete resection and survival was assessed. Prediction of complete resection was compared with computed tomography (CT) when available.
resultsSeventy-four (70%) patients achieved complete resection. WB-DWI/MRI-predicted complete resection with 97.3% sensitivity, 83.9% specificity and 93.3% accuracy. MRI-based complete resection prediction, complete resection at IDS, and serum CA-125 significantly affected progression-free survival (MRI: Hazard Ratio [HR] = 5.43, IDS: HR = 4.19, CA-125: HR = 1.68; p < 0.01) with the first two parameters also significantly affecting overall survival (MRI: HR = 4.24, IDS: HR = 2.87; p < 0.01). Multivariate analysis confirmed MRI-based complete resection prediction and serum CA-125 as significant for progression-free (p < 0.001 and p = 0.04) and MRI-based prediction significant for overall survival (p < 0.001). In a 69-patient subanalysis, WB-DWI/MRI-predicted complete resection was significantly better than CT (91.3% vs. 72.5% accuracy, p < 0.001).
conclusionWB-DWI/MRI after NACT is accurate for predicting surgical and survival outcomes in patients with non-primary resectable ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.